Christos Vaklavas,
MD
Languages Spoken: English, German, Modern Greek (1453-)
Throughout his career, Dr. Vaklavas has developed a series of research activities in breast cancer that span the entire spectrum from lab-based research to clinical trials. In the lab, his focus has been on translation (mRNA to protein) and the discovery of compounds that disrupt oncogenic translation. This research has been supported by a Young Investigator Award from ASCO and a Career Catalyst Award in Basic and Translational Research from Susan G Komen.
As the Physician Leader in Breast Cancer at Huntsman Cancer Institute, he oversees all clinical research conducted in the Institute pertaining to breast cancer. He oversees the clinical trials portfolio and serves as the Principal Investigator for many clinical trials including investigator-initiated studies that intend to bring the highly innovative basic science conducted at Huntsman Cancer Institute closer to clinical applications.
Clinical Locations
801-213-3200
Clinic 3A, Center for Breast Health
801-587-4241
Fax: (801) 585-3520
Specialties
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Associate Professor |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology) |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.8/ 5
Care provider's explanation of condition/problem
4.8/ 5
Care provider's effort to include me in decisions
4.8/ 5
Wait time at clinic
4.5/ 5
Care provider's concern for questions & worries
4.8/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
March 25, 2022
FARMINGTON HEALTH CENTER
Dr. Vaklavas is wonderful. He has a sense of humor that helps alleviate my tension/anxiety. He is truely concerned with my care. He's a kind person.
UofU Patient
March 21, 2022
HUNTSMAN CANCER CENTER
None just wish he was in Elko
UofU Patient
March 18, 2022
HUNTSMAN CANCER CENTER
Very compsionate
UofU Patient
February 25, 2022
HUNTSMAN CANCER CENTER
Normally the doctor is great. This time I felt he was distant. Told me no more scans, tests, but no explanation of that. I wanted to ask more questions but I felt self conscious about it this time. I can't put my finger on it really. I think he thinks I don't want other treatment because I was afraid to take Ibrannce because of another medical condition I have. And since then he has seemed distant. But I'm not a good communicator myself at the doctor's office. I should have asked more questions.
UofU Patient
February 21, 2022
HUNTSMAN CANCER CENTER
They have always included me in the process of my care & have gave me many options & good advice!
UofU Patient
February 14, 2022
HUNTSMAN CANCER CENTER
Best experience of my life!!! I felt loved and cared about by all who helped make this appointment possible
UofU Patient
February 14, 2022
HUNTSMAN CANCER CENTER
Dr always listens always explains
UofU Patient
February 03, 2022
FARMINGTON HEALTH CENTER
Dr V (I can't spell his name!) is always so attentive and helpful. Very professional!
UofU Patient
January 25, 2022
HUNTSMAN CANCER CENTER
My oncologist, Dr. Vaklavas, is truly one in a million. He and his staff have literally been at my side throughout my cancer diagnosis and all of the hideous treatments. He has been unfailingly kind and empathetic, and has shown a degree of humility seldom seen in physicians of his caliber. He always answers my questions in a way that I can understand, he takes my concerns into consideration, he has been patient and caring to me and my husband throughout my ordeal. If this had to happen to me, thank God that I had Dr. Vaklavas and his amazing staff to rely on as we navigated through my cancer treatments. They are part of what has turned Huntsman Cancer Hospital into a world class facility.
UofU Patient
January 23, 2022
FARMINGTON HEALTH CENTER
Bad support staffSaw Dr briefly before his nurse ushered him out
UofU Patient
January 23, 2022
HUNTSMAN CANCER CENTER
Great care
UofU Patient
January 13, 2022
HUNTSMAN CANCER CENTER
I love Dr Vaklavos as he addresses all medical very holistic approach. He and the nurse work well together and explain everything
UofU Patient
January 09, 2022
FARMINGTON HEALTH CENTER
I felt like I was important and that I mattered unlike I felt with my previous oncologist.
UofU Patient
December 07, 2021
FARMINGTON HEALTH CENTER
There is definitely a communication problem in this clinic, I don't believe it's the doctor, but it does interfere with his treatment when you do not get told of changes
UofU Patient
November 08, 2021
HUNTSMAN CANCER CENTER
Very good and take care of people when they come in good service
UofU Patient
October 05, 2021
FARMINGTON HEALTH CENTER
My doctor and nursing staff were helpful and informative. They offered me information and options.
UofU Patient
September 23, 2021
FARMINGTON HEALTH CENTER
Dor voklavas and anna are great
UofU Patient
August 30, 2021
HUNTSMAN CANCER CENTER
From Idaho so if any one asked about my care I would tell them about you
UofU Patient
August 15, 2021
HUNTSMAN CANCER CENTER
Dr. Vaklavas is a wonderful doctor and care provider, he never makes you feel rushed and every question is important to him.
UofU Patient
July 20, 2021
HUNTSMAN CANCER CENTER
It would be hard to overstate our gratitude to Dr. Vaklavas. He has been our guiding light throughout my terrible cancer ordeal. He is a devoted listener and has never failed to respond to my questions, fears and concerns. He has always treated me with the utmost kindness, respect, and competence. He exhibits a humility that Illustrates what a magnificent man and doctor he is. His patients are very well served. Thank you to this extraordinary man and his wonderful staff. My husband and I will forever be in his debt.
UofU Patient
July 20, 2021
FARMINGTON HEALTH CENTER
Dr. V and anna area wonderful
UofU Patient
June 22, 2021
FARMINGTON HEALTH CENTER
dr voklovas is outstanding
UofU Patient
June 10, 2021
HUNTSMAN CANCER CENTER
He is fabulous. He took the time to research other conditions I have prior to my visit. Very caring, funny in a good way.
UofU Patient
May 31, 2021
HUNTSMAN CANCER CENTER
good
UofU Patient
May 28, 2021
HUNTSMAN CANCER CENTER
every thing was explained in terms I could understand.
UofU Patient
May 26, 2021
HUNTSMAN CANCER CENTER
I'm just upset that suddenly he was being paged or something and I felt rushed. I've been I such bad pain in my chest area as of the last 4 weeks and here I am being ignored again. Old CT scans don't show new anything. I need a nerve abalation on my ribs near my heart. the pain is getting worse. he kept getting calls and pages and I am wondering if a patient was having an all out emergancy because that usually never ever happens. I just get upset because I have to take so much time and effort get to these appointments and I feel cheated when I can't atleast have time to show my serious concerns . I just don't feel like they matter and that hurts my feelings very much. I get that people are paying and calling but o was rushed out of the office after that. also, the new people in the front registration area are rude and incompetent. Alwats goes to voicemail where as before that rarely Happened.
UofU Patient
May 24, 2021
HUNTSMAN CANCER CENTER
Dr V took a great deal of time to understand my concerns and discuss options and treatment plans. I felt respected and assured of a high quality of care.
UofU Patient
May 04, 2021
FARMINGTON HEALTH CENTER
Dr. Vaklavas and Nurse Anna are wonderful. They take care of me. But I won't ever go back to Farmington Huntsman again. It's toxic.
UofU Patient
May 03, 2021
FARMINGTON HEALTH CENTER
Excellent communication. Answered all question thoroughly. Very patient and understanding.
UofU Patient
April 23, 2021
HUNTSMAN CANCER CENTER
Both the doctor and the nurse had very positive and friendly personalities.
UofU Patient
March 25, 2021
HUNTSMAN CANCER CENTER
Good
UofU Patient
March 20, 2021
HUNTSMAN CANCER CENTER
all good
UofU Patient
February 26, 2021
HUNTSMAN CANCER CENTER
this dr was very good at taking this experience down a couple of notches by his ability to make this situation not so worry some.
UofU Patient
February 22, 2021
HUNTSMAN CANCER CENTER
Good
UofU Patient
February 10, 2021
HUNTSMAN CANCER CENTER
Both doctor and nurse were caring, never made me feel rushed, and answered all my questions & concerns with great knowledge and examples. Made me feel great!
UofU Patient
February 07, 2021
FARMINGTON HEALTH CENTER
I appreciated having my concerns listened to.
UofU Patient
February 06, 2021
HUNTSMAN CANCER CENTER
good experience
UofU Patient
January 31, 2021
HUNTSMAN CANCER CENTER
Dr Vaklavas was very thorough and caring.
UofU Patient
January 27, 2021
HUNTSMAN CANCER CENTER
Dr. Vaklvas and Torie are kind, funny, brilliant, and I know with them I am receiving the best care possible. They make it possible for me to understand and accept my cancer experience for what it is, and as a result I can jump back into my life with joy and enthusiasm.
UofU Patient
January 18, 2021
HUNTSMAN CANCER CENTER
Dr Vaklavas has been nothing short of a gift from God for me and my husband. He has been continuously kind, thoughtful, courteous, caring, and competent. He has provided me with clear explanations for everything that was going to occur as we fought my breast cancer. He has unfailingly listened to my concerns. He has always responded to my messages, whether by phone or via MyChart. He has treated me with the utmost respect. We will bless him forever for the person he is and the care he has provided.
UofU Patient
January 18, 2021
FARMINGTON HEALTH CENTER
THIS DR. IS AN EXCELLANT PEOPLE PERSON. HE TAKES THE TIME TO GO OVER ANY CONCERNS I HAVE AND ECPLAINS ALL THINGS IN DETAIL AND MAKES SURE I UNDERSTAND. I THINK HE IW WONDERFUL !!
UofU Patient
January 15, 2021
HUNTSMAN CANCER CENTER
Dr. Vaklavas is the best
UofU Patient
December 27, 2020
HUNTSMAN CANCER CENTER
He took the time to explain things!
UofU Patient
December 04, 2020
HUNTSMAN CANCER CENTER
Good Experience
UofU Patient
November 29, 2020
HUNTSMAN CANCER CENTER
Dr Vaklavas is one of the most engaged physicians I have met. He explained research and treatment options in depth.
UofU Patient
November 10, 2020
HUNTSMAN CANCER CENTER
Dr. Vaklavas is knowledgable and caring. The fellow that saw me was also very helpful.
UofU Patient
November 08, 2020
HUNTSMAN CANCER CENTER
good
UofU Patient
October 29, 2020
FARMINGTON HEALTH CENTER
The dr explained a lot and answered a lot of my queations . he is wonderful and i would highly reccomend him
UofU Patient
October 23, 2020
HUNTSMAN CANCER CENTER
A+ results
UofU Patient
October 12, 2020
HUNTSMAN CANCER CENTER
excellent. I really liked the doctor.
Throughout his career, Dr. Vaklavas has developed a series of research activities in breast cancer that span the entire spectrum from lab-based research to clinical trials. In the lab, his focus has been on translation (mRNA to protein) and the discovery of compounds that disrupt oncogenic translation. This research has been supported by a Young Investigator Award from ASCO and a Career Catalyst Award in Basic and Translational Research from Susan G Komen.
As the Physician Leader in Breast Cancer at Huntsman Cancer Institute, he oversees all clinical research conducted in the Institute pertaining to breast cancer. He oversees the clinical trials portfolio and serves as the Principal Investigator for many clinical trials including investigator-initiated studies that intend to bring the highly innovative basic science conducted at Huntsman Cancer Institute closer to clinical applications.
Academic Locations
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Associate Professor |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology) |
Research Interests
- Functional Precision Oncology
- Translational Genomics
- Phase I and II Clinical Trials
- Platform Clinical Trials
- Breast Cancer
- Translation
Selected Publications - Journal Articles
Journal Article
- Adriana M Coletta, Mary C Playdon, Kelly G Baron, Mei Wei, Kristen Kelley, Christos Vaklavas, Anna Beck, Saundra S Buys, Jonathan Chipman, Cornelia M Ulrich, Darren Walker, Shelley White, Sonal Oza, Rebecca W Zingg, Pamela A Hansen (2021). The association between time-of-day of habitual exercise training and changes in relevant cancer health outcomes among cancer survivors. PLoS One, 16(10).
- Paula I Gonzalez-Ericsson, Julia D Wulfkhule, Rosa I Gallagher, Xiaopeng Sun, Margaret L Axelrod, Quanhu Sheng, Na Luo, Henry Gomez, Violeta Sanchez, Melinda Sanders, Lajos Pusztai, Emanuel Petricoin, Kim R M Blenman, Justin M Balko, I-SPY2 Trial Team (2021). Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. Clin Cancer Res.
- Stringer-Reasor EM, May JE, Olariu E, Caterinicchia V, Li Y, Chen D, Della Manna DL, Rocque GB, Vaklavas C, Falkson CI, Nabell LM, Acosta EP, Forero-Torres A, Yang ES (2021). An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer. . Breast Cancer Res, 23(1).
- Chae YK, Hong F, Vaklavas C, Cheng HC, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, ODwyer PJ, Chen AP, Flaherty KT (2020). A Phase II Study of AZD4547 in Patients with Tumors harboring Aberrations in the FGFR Pathway: Results from the NCI-MATCH Trial (EAY131) Sub-protocol W. J Clin Oncol, 38(21), 2407-2417.
- Vaklavas C, Roberts BS, Varley KE, Lin NU, Liu MC, Rugo HS, Puhalla S, Nanda R, Storniolo AM, Carey LA, Saleh MN, Li Y, Delossantos JF, Grizzle WE, LoBuglio AF, Myers RM, Forero-Torres A on behalf of the Translational Breast Cancer Research Consortium (2020). TBCRC 002: A phase II, randomized, open label trial of preoperative letrozole with or without bevacizumab in post-menopausal women with newly diagnosed stage II/III hormone receptor positive and HER2 negative breast cancer. Breast Cancer Res, 22(1).
- Vaklavas C, Blume SW, Grizzle WE (2020). Hallmarks and Determinants of Oncogenic Translation Revealed by Ribosome Profiling in Models of Breast Cancer. . Transl Oncol, 13(2), 452-470.
- Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, Winer EP, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Park BH, Wahl RL, Stearns V (2019). TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. J Clin Oncol, 37(9), 714-722.
- Vaklavas C, Zinn KR, Samuel SL, Meng Z, Grizzle WE, Choi H, Blume SW (2018). Translational control of the undifferentiated phenotype in ER‑positive breast tumor cells: Cytoplasmic localization of ERα and impact of IRES inhibition. Oncol Rep, 39(6), 2482-2498.
- Vaklavas C, Blume SW, Grizzle WE (2017). Translational Dysregulation in Cancer: Molecular Insights and Potential Clinical Applications in Biomarker Development. Front Oncol, 7, 158.
- Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M, Giles FJ (2016). Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget, 8(9), 16052-16074.
- Vaklavas C, Grizzle WE, Choi H, Meng Z, Zinn KR, Shrestha K, Blume SW (2016). IRES inhibition induces terminal differentiation and synchronized death in triple-negative breast cancer and glioblastoma cells. Tumour Biol, 37(10), 13247-13264.
- Rugo HS, et al, I-SPY2 Investigators (2016). Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med, 375(1), 23-34.
- Park JW, et al, I-SPY2 Investigators (2016). Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med, 375(1), 11-22.
- Forero A, Li Y, Chen D, Grizzle WE, Updike KL, Merz ND, Downs-Kelly E, Burwell TC, Vaklavas C, Buchsbaum DJ, Myers RM, LoBuglio AF, Varley KE (2016). Expression of the MHC Class II Pathway in Triple-Negative Breast Cancer Tumor Cells Is Associated with a Good Prognosis and Infiltrating Lymphocytes. Cancer Immunol Res, 4(5), 390-9.
- Morris GJ, Dawood S, Cortes J, Ward JH, Vaklavas C, Forero A, Ward S, Toppmeyer D (2015). Sub-centimeter HER2-Positive Breast Cancer: How Small Is Too Small to Treat? Semin Oncol, 42(4), e67-79.
- Turner NC, et al, PALOMA3 Study Group (2015). Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med, 373(3), 209-19.
- Paoletti C, Li Y, Muiz MC, Kidwell KM, Aung K, Thomas DG, Brown ME, Abramson VG, Irvin WJ Jr, Lin NU, Liu MC, Nanda R, Nangia JR, Storniolo AM, Traina TA, Vaklavas C, Van Poznak CH, Wolff AC, Forero-Torres A, Hayes DF, Translational Breast Cancer Research Consortium TBCRC (2015). Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Clin Cancer Res, 21(12), 2771-9.
- Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ Jr, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC, Translational Breast Cancer Research Consortium TBCRC (2015). TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer. Clin Cancer Res, 21(12), 2722-9.
- Vaklavas C, Meng Z, Choi H, Grizzle WE, Zinn KR, Blume SW (2015). Small molecule inhibitors of IRES-mediated translation. Cancer Biol Ther, 16(10), 1471-85.
- Vaklavas C, Forero A (2014). Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE). BioDrugs, 28(3), 253-63.
- Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R (2014). Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. Hepatogastroenterology, 60(127), 1611-23.
- Vaklavas C, Meredith RF, Shen S, Knox SJ, Micallef IN, Shah JJ, LoBuglio AF, Forero-Torres A (2013). Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma. Cancer Biother Radiopharm, 28(5), 370-9.
- Yadav BS, Bansal A, Sharma SC, Javid SH, Anderson BO, Vaklavas C, Forero A, Ravi V, Patel S, Boudadi K, Chugh R, Morris GJ (2013). A 62-year-old woman with osteogenic sarcoma in the contralateral breast 15 years after treatment for breast cancer. Semin Oncol, 40(2), 135-44.
- Vaklavas C, Forero-Torres A (2013). Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Ther Adv Hematol, 3(4), 209-25.
- Garrido-Laguna I, Janku F, Vaklavas C, Falchook GS, Fu S, Hong DS, Naing A, Tsimberidou AM, Wen S, Kurzrock R (2011). Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer, 118(5), 1422-8.
- Vaklavas C, Ross JR, Nabell LM, Forero A, Heslin MJ, Wood TE (2012). By the pricking of my thumbs, something wicked this way comes: sporadic cancers versus eponymous hereditary cancer predisposition syndromes. J Natl Compr Canc Netw, 10(1), 7-13.
- Vaklavas C, Steciuk MR, Ren Y, Baird MF, Mikhail FM, Foran JM (2011). A case of acute promyelocytic leukemia without RARα rearrangement and apparently normal cytogenetics. Clin Lymphoma Myeloma Leuk, 11(6), 521-4.
- Vaklavas C, Forero-Torres A (2011). How do I treat "triple-negative" disease. Curr Treat Options Oncol, 12(4), 369-88.
- Vaklavas C, Chatzizisis YS, Tsimberidou AM (2011). Common cardiovascular medications in cancer therapeutics. Pharmacol Ther, 130(2), 177-90.
- Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R (2010). Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. Cancer, 117(1), 77-85.
- Vaklavas C, Sotelo-Rafiq EP, Lovy J, Escobar MA, Tsimberidou AM (2010). Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression. Virol J, 7, 256.
- Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD (2010). Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf, 33(3), 171-87.
- Guerrouahen BS, Futami M, Vaklavas C, Kanerva J, Whichard ZL, Nwawka K, Blanchard EG, Lee FY, Robinson LJ, Arceci R, Kornblau SM, Wieder E, Cayre YE, Corey SJ (2010). Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res, 16(4), 1149-58.
- Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM (2010). Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist, 15(2), 130-41.
- Aguilera DG, Vaklavas C, Tsimberidou AM, Wen S, Medeiros LJ, Corey SJ (2009). Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience. J Pediatr Hematol Oncol, 31(11), 803-11.
- Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R (2009). Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience. J Clin Endocrinol Metab, 94(11), 4423-32.
- Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD (2008). Molecular basis of statin-associated myopathy. Atherosclerosis, 202(1), 18-28.
- Vaklavas C, Tefferi A, Butterfield J, Ketterling R, Verstovsek S, Kantarjian H, Pardanani A (2006). 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leuk Res, 31(5), 691-4.
- Christakis C, Vaklavas C, Kontos N, Chatzidimitriou C, Tzelepi K, Karanikas M, Christakis E (2005). Pelvic reconstruction of the retroperitoneum after abdominoperineal resection of the rectum using full-thickness skin grafts. Tech Coloproctol, 8 Suppl 1, s85-8.
Book Chapter
- Vaklavas C, LoBuglio AF, Saleh M, Yelin M, Forero A (2013). CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE). In Antibody-Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications; Cancer Drug Discovery and Development series (pp. 211-20). Springer.
- Forero A, Vaklavas C, LoBuglio AF (2013). Brentuximab Vedotin (SGN-35) for CD30 Positive Malignancies. In Antibody- Drug Conjugates and Immunotoxins: From Pre-Clinical Development to Therapeutic Applications; Cancer Drug Discovery and Development series (pp. 161-75). Springer.
Editorial
- Welm BE, Vaklavas C, Welm AL (2021). Toward improved models of human cancer. 5(1).
- Vaklavas C, Chatzizisis YS (2010). The changing perspective of cardiology in cancer care. Expert Rev Cardiovasc Ther, 9(1), 1-3.